Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D Supplementation and Low-Grade Inflammation in Deficient Adults: Study Summary

Previous related pageVitamin D Supplementation and Low-Grade Inflammation in Deficient Adults: Full StudyNext related pageVitamin D, CTLA-4 and Immune Restraint: Full Study
Study at a glance

How was vitamin D tested for inflammation in adults with low levels?

Researchers randomly assigned 65 adults aged 18 to 60 to vitamin D or a placebo, a treatment without vitamin D. Participants had low vitamin D levels and overweight or obesity. The trial lasted 16 weeks. The reported analysis included 54 participants who followed the required study steps.

Did raising vitamin D levels improve signs of inflammation?

Vitamin D blood levels rose from about 31 to 88 nmol/L in the supplement group, while changing little with placebo. Despite this rise, vitamin D did not clearly improve the measured signs of inflammation compared with placebo. An immune-cell signalling measurement decreased in both groups, so the decrease could not be credited to vitamin D alone.

Does this rule out every effect of vitamin D on inflammation?

Raising a low vitamin D blood level did not automatically improve the inflammatory measurements studied. This does not prove that vitamin D has no effect on inflammation anywhere in the body. The trial measured selected outcomes, rather than every tissue, long-term immune function or inflammatory disease. Some substances were too low for the tests to measure reliably.

Do these studies establish a treatment for inflammation?

The trial was small, and inflammation was not its main outcome. It could not rule out every possible effect. In a separate, longer analysis from the trial called VITAL involving older people, one inflammation marker was lower at two years but not at four years. Other inflammatory substances showed no consistent benefit. These results do not establish an anti-inflammatory treatment, supplement dose or target blood level.

Read the full article below ↓

A randomised trial in adults with low vitamin D concentrations and overweight or obesity found that supplementation raised vitamin D status but did not clearly improve the measured inflammatory outcomes over 16 weeks. This is a useful test of the assumption that correcting low status must reduce inflammation. The result did not support that assumption for the outcomes studied. Read the companion Vitamin D Supplementation and Low-Grade Inflammation in Deficient Adults: Full Study.

The study in brief

Mousa and colleagues randomised 65 adults aged 18 to 60 years with body mass index at least 25 kg/m² and 25-hydroxyvitamin D no higher than 50 nmol/L. The per-protocol analysis included 54 participants. The research regimen used a loading dose followed by daily supplementation; it is not a personal dosing recommendation.

Mean 25-hydroxyvitamin D rose from about 31.4 to 88.4 nmol/L in the vitamin D group, compared with 34.2 to 36.1 nmol/L with placebo. The intervention therefore changed the measured vitamin D status substantially. Vitamin D Status vs Vitamin D Effect explains why this exposure result must be separated from the downstream biological outcome.

What happened to inflammation?

There was no clear between-group improvement in high-sensitivity C-reactive protein or NF-κB activity. NF-κB declined in both groups, so a before-and-after reduction in the supplemented participants cannot be credited to vitamin D alone. The placebo comparison is essential to the interpretation.

Other cytokine results did not establish a coherent anti-inflammatory benefit. Some analytes were undetectable in many samples, limiting what could be concluded about them. An assay’s inability to quantify a marker is not evidence that the biological process was absent.

These results concern selected measurements relevant to Vitamin D and Chronic Inflammation. They do not measure every inflamed tissue, long-term immune function or inflammatory disease event. The signalling result is likewise a specific human measurement, not a refutation of every laboratory mechanism discussed in Vitamin D and Inflammatory Signalling.

How certain is the result?

The study’s randomised design and substantial rise in vitamin D status are strengths. Its small analysed sample, per-protocol analysis and secondary inflammatory outcomes limit precision. It did not demonstrate benefit, but it was not an equivalence trial proving that every possible effect was zero.

A longer VITAL biomarker analysis provides context. In that different, older population, vitamin D was associated with lower hs-CRP at two years, but the finding was not sustained at four years and there was no consistent beneficial cytokine pattern. The two studies should not be treated as identical tests or combined into a universal verdict.

The results do not establish correction of the excessive immune activity discussed in Vitamin D and Immune Overactivation. Nor did the study show that oxidative stress mediated its measured responses; Vitamin D and Oxidative Stress explains that related physiological topic. Differences in population and duration matter when comparing this trial with VITAL; Why Vitamin D Results Differ provides context for interpreting those differences without turning either study into a universal verdict.

Conclusion

Raising vitamin D status did not automatically reduce the measured inflammatory responses in this deficient population. The evidence supports outcome-specific interpretation rather than an anti-inflammatory treatment claim. It does not establish a supplement dose, a target blood concentration or an effect on Vitamin D and Immune Ageing.

This page is an original Vitamin D3 For Life explanation and critical appraisal of the research cited below.

Primary source and publication details

Related reading

Original sources

Source

Effect of vitamin D supplementation on inflammation and nuclear factor kappa-B activity in overweight/obese adults: a randomized placebo-controlled trial

Yet, no trials have examined the effects of vitamin D supplementation on NFκB activity in-vivo in humans.

Publication details

Effect of vitamin D supplementation on inflammation and nuclear factor kappa-B activity in overweight/obese adults: a randomized placebo-controlled trial. Aya Mousa, Negar Naderpoor, Josphin Johnson, Karly Sourris, Maximilian P J de Courten, Kirsty Wilson, Robert Scragg, Magdalena Plebanski, Barbora de Courten. Scientific Reports; 2017; 7; 15154. DOI: 10.1038/s41598-017-15264-1. CC BY. This page provides an original explanatory appraisal; no source figures are reproduced.

Read more →
Source

Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial

Background: The VITAL study was a nationwide, randomized, double-blind, placebo-controlled, 2 × 2 factorial trial of vitamin D3 (2000 IU/day) and marine n-3 FAs (1 g/day) supplements.

Publication details

Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial. Yanbin Dong, Haidong Zhu, Li Chen, Ying Huang, William Christen, Nancy R Cook, Trisha Copeland, Samia Mora, Julie E Buring, I-Min Lee, Karen H Costenbader, JoAnn E Manson. Nutrients; 2022; 14; 24; 5307. DOI: 10.3390/nu14245307. CC BY. This page provides an original explanatory appraisal; no source figures are reproduced.

Read more →